Print this page
radiation
-
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
Protocol: 052008Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors.
Protocol: 052208Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications.
Protocol: 052302Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Protocol: 052305Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and
Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult
Subjects with Advanced Solid Malignancies
Protocol: 052401Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination with a MEK inhibitor PD-0325901 in Patients with Advanced or Refractory Solid Tumors.
Protocol: 052403Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors
Protocol: 052404Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.
Protocol: 071807Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Colon -
Modified FOLFIRINOX Alternated with Biweekly Gemcitabine plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas.
Protocol: 072011Principal Investigator:
-
Lyudmyla Berim
Applicable Disease Sites: Pancreas -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Liver -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Pancreas -
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
Protocol: 072108Applicable Disease Sites: Pancreas
-
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Rectum -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Colon -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver